Pfizer (PFE) earnings Q1 2026

Pfizer on Tuesday posted first-quarter earnings and income that topped estimates and reaffirmed its 2026 outlook, as lately launched and purchased merchandise present development.

Here’s what the corporate reported for the primary quarter in contrast with what Wall Street was anticipating, primarily based on a survey of analysts by LSEG:

• Earnings per share: 75 cents adjusted vs. 72 cents anticipated
• Revenue: $14.45 billion vs. $13.79 billion anticipated

The pharmaceutical big is trying to longer-term investments in its pipeline, together with its current $10 billion acquisition of the obesity biotech Metserato counter waning Covid product gross sales and declines from older medicine. Pfizer is targeted on a number of essential information releases this yr, together with late-stage trial outcomes on an experimental targeted drug in lung most cancers.